Welcome
Support Centre
21 May 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Topical zinc oxide for open pilonidal sinus wounds: a randomised, double-blind, placebo-controlled multicentre trial
ISRCTN ISRCTN35311675
ClinicalTrials.gov identifier
Public title Topical zinc oxide for open pilonidal sinus wounds: a randomised, double-blind, placebo-controlled multicentre trial
Scientific title
Acronym ZÅRSTUDIET
Serial number at source N/A
Study hypothesis Locally applied zinc oxide (ZnO) may be beneficial for various types of human wounds. This randomised, double-blind, placebo-controlled multicentre trial compared the effect of topical ZnO with placebo under moist conditions on the healing of excisional wounds following surgical removal of the pilonidal sinus.
Lay summary
Ethics approval No ethics information required at time of registration.
Study design Randomised controlled trial
Countries of recruitment Denmark
Disease/condition/study domain Pilonidal excisional wound
Participants - inclusion criteria Patients, 18 years or older, with a first-episode of pilonidal abscess requiring surgery are included after giving their written informed consent.
Participants - exclusion criteria Previous pilonidal surgery, hypersensitivity to zinc, dementia, insufficiency in Danish, pregnancy or lactation.
Anticipated start date 01/02/2002
Anticipated end date 01/05/2004
Status of trial Completed
Patient information material
Target number of participants 75
Interventions Zinc oxide and polyvinylpyrrolidone versus polyvinylpyrrolidone alone
Primary outcome measure(s) Time to wound closure in days, defined by complete coverage of the
wound with visible epithelium.
Secondary outcome measure(s) Secondary outcomes were:
1. Postoperative antibiotic treatment
2. Re-operations
3. Pain intensity
4. Adverse events

Tertiary outcomes were:
1. Serum-zinc levels
2. Sick leave
Sources of funding Apotekerfonden 1991, Abigo Medical AB
Trial website
Publications 2006 results in http://www.ncbi.nlm.nih.gov/pubmed/17014663
Contact name Dr  Magnus  Ågren
  Address Department of Surgery K
Bispebjerg Hospital
University of Copenhagen
Bispebjerg Bakke 23
  City/town Copenhagen
  Zip/Postcode DK-2400
  Country Denmark
  Tel +45 35316493
  Fax +45 35312981
  Email magnus.agren@get2net.dk
Sponsor Bispebjerg Hospital (Denmark)
  Address Department of Surgery K
Bispebjerg Hospital
University of Copenhagen
Bispebjerg Bakke 23
  City/town Copenhagen
  Zip/Postcode DK-2400
  Country Denmark
  Tel +45 35316493
  Fax +45 35312981
  Email magnus.agren@get2net.dk
Date applied 20/09/2004
Last edited 25/09/2009
Date ISRCTN assigned 29/09/2004
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central